{"messages":[{"status":"ok","category":"all"}], "collection":[{"title":"De novo design of flexible protein interactions with GuideFlip","authors":"Yi, K.; Chen, Q.; Zhang, D.; Tian, P.; Wagstaff, J. L.; McLaughlin, S. H.; Tate, C. G.; Jamali, K.; Scheres, S. H. W.","author_corresponding":"Sjors H.W. Scheres","author_corresponding_institution":"MRC Laboratory of Molecular Biology","doi":"10.64898\/2026.09.27.754145","date":"2026-09-28","version":"1","type":"new results","license":"cc_by","category":"biophysics","jatsxml":"https:\/\/www.biorxiv.org\/content\/early\/2026\/09\/28\/2026.09.27.754145.source.xml","abstract":"De novo design of protein binders requires a target structure. However, for flexible targets, such as intrinsically disordered proteins, this structure does not exist until the binder has stabilized the interaction. Such targets are therefore difficult for methods that separate structure generation from sequence design. We introduce GuideFlip, which co-designs structure and sequence through guided discrete flow matching: binder residues are assigned progressively while the complex is re-predicted at each step, allowing the evolving interface to affect the design process. GuideFlip reduces the hydrophobic bias of direct AlphaFold optimization and improves in silico success rates over existing approaches. We release a database of binder candidates for 177 human disordered proteins. Experimentally, we obtain de novo binders to the C-terminus of -synuclein and the disordered amino terminus of RBX1 with hit rates of 13.5% and 41.7%, respectively, and we confirm the epitopes of selected binders by NMR and mutagenesis. Applying GuideFlip to flexibility on the binder side, we design a nanobody that binds the agonist-bound {beta}1-adrenergic receptor in the active state, but not the receptor in its inactive state, with a 75% hit rate and cryo-EM structure confirming the design. GuideFlip enables protein design where bound structures emerge only upon binding.","published":"NA","server":"bioRxiv"},{"title":"De novo design of flexible protein interactions with GuideFlip","authors":"Yi, K.; Chen, Q.; Zhang, D.; Tian, P.; Wagstaff, J. L.; McLaughlin, S. H.; Tate, C. G.; Jamali, K.; Scheres, S. H. W.","author_corresponding":"Sjors H.W. Scheres","author_corresponding_institution":"MRC Laboratory of Molecular Biology","doi":"10.64898\/2026.09.27.754145","date":"2026-09-30","version":"2","type":"new results","license":"cc_by","category":"biophysics","jatsxml":"https:\/\/www.biorxiv.org\/content\/early\/2026\/09\/30\/2026.09.27.754145.source.xml","abstract":"De novo design of protein binders requires a target structure. However, for flexible targets, such as intrinsically disordered proteins, this structure does not exist until the binder has stabilized the interaction. Such targets are therefore difficult for methods that separate structure generation from sequence design. We introduce GuideFlip, which co-designs structure and sequence through guided discrete flow matching: binder residues are assigned progressively while the complex is re-predicted at each step, allowing the evolving interface to affect the design process. GuideFlip reduces the hydrophobic bias of direct AlphaFold optimization and improves in silico success rates over existing approaches. We release a database of binder candidates for 177 human disordered proteins. Experimentally, we obtain de novo binders to the C-terminus of -synuclein and the disordered amino terminus of RBX1 with hit rates of 13.5% and 41.7%, respectively, and we confirm the epitopes of selected binders by NMR and mutagenesis. Applying GuideFlip to flexibility on the binder side, we design a nanobody that binds the agonist-bound {beta}1-adrenergic receptor in the active state, but not the receptor in its inactive state, with a 75% hit rate and cryo-EM structure confirming the design. GuideFlip enables protein design where bound structures emerge only upon binding.","published":"NA","server":"bioRxiv"}]}